BCLI BRAINSTORM CELL THERAPEUTICS INC Capital Structure Changes 8-K Filing 2025 - Nasdaq Compliance Extension On March 25, 2025, Brainstorm Cell Therapeutics Inc. received an extension from the Nasdaq Hearings Panel until June 30, 2025, to regain compliance with listing requirements, specifically to meet a $2.5 million minimum stockholders equity requirement.Get access to all SEC 8-K filings of the BRAINSTORM CELL THERAPEUTICS INC